plotted, but this is not always practical. The accumulation of mitotic figures in patients injected with 10 mg colcemid intravenously 2 hours before commencement of surgery has been estimated as follows: in 'normal colonic mucosa' (12 specimens), mean 35, range 19-71 mitoses/100 cells/hour; in colorectal carcinoma (19 specimens), mean 20, range 9-33 mitoses/100 cells/hour. It will be seen that there is a general rise in mitotic rate with progressive dedifferentiation. Detailed examination of the specimens showed that there is often considerable variation within a specimen and that two tumours of apparently the same histological type may have very different proliferative activity. In general terms, the overall proliferative activity of the tumours is less than the proliferative zones of 'normal colonic mucosa' taken from the same specimen. So far we know little of the functional organization of colonic tumour cells populations. It is unknown what proportion of the cells are clonogenic, that is, retain all the information for producing an independent line of tumour cells, and what proportion has only a capacity for limited division and whose progeny will inevitably die. Furthermore, it is unknown how many of the apparently nondividing cells are resting and retain the capacity to proliferate (Go) and how many are true endcells that are going to be lost. Whatever method is used to calculate the proliferative potential of the tumour, it is found that at least 95% of its daily cell production is lost (Charbit et al. 1971 , Cooper 1973 .
Animal Models A variety of chemicals can induce intestinal neoplasms but most of them cause cancers coincidentally in several other organs (Weisburger 1971) . Injections of dimethyl hydrazine induce adenomatous polyps and adenocarcinomas in mice that have a close resemblance to their counterparts in man (Pegg & Hawks 1971) . This model can produce a 100% incidence of colorectal tumour in the animals without inducing any other form of cancer and these tumours appear inevitably after a critical dose of the carcinogen has been given, so that injections can be terminated before the development of tumours and their evolution can be studied. Unfortunately, dimethyl hydrazine is very toxic and hepatic damage accompanies the tumours. The proliferative activity of the tumours is variable: some are relatively quiescent, others contain large numbers of mitotic figures. Nevertheless, the tumour doubling time is slow: at 22 weeks the polyps were 1-2 mm in diameter and at 30 weeks they were 2-4 mm. This slow growth was associated with many microscopic signs of a high rate of cell turnover. It It is unlikely that changes in surgical technique will yield significant improvements in treatment results in rectal cancer in terms of patient survival unless innovations in detection methods lead to important modifications of the pattern of stage distribution at presentation. Since more than 50% of rectal cancer patients die from the disease, it is important to reconsider the role of alternative treatment methods used either alone, in combination, or as adjuncts to surgery.
Consideration of surgical results in relation to pathological stage shows that tumours confined to the bowel wall have a high probability of cure by resection, whereas associated involvement of the draining lymph nodes (Dukes C) sharply reduces the patient's chance of cure. In -the latter group preoperative irradiation is a logical choice as an adjunct to surgery and initial results are encouraging (Dwight et al. 1972 ), but its value remains to be established. The use of nonsurgical treatment (either chemotherapy or radiotherapy, or both in combination) before surgical exploration raises the problem of staging both as an indicator of prognosis and to define the extent of disease for accurate radiotherapy planning. This is particularly important if additional treatment is to be avoided in those patients with localized disease where the prognosis after surgery alone is excellent. At present there is no accurate method of clinical staging. Lower limb lymphography will demonstrate retroperitoneal node involvement in abdominal disease with extension to the pelvic wall (Fig IA) , but generally fails to opacify the internal iliac nodes. Attempts have been made to opacify the nodes draining the rectum by injecting contrast medium into the mucosa per rectum, but this is of doubtful value (Kapandji & Parturier-Albot 1972) . Scanning with gallium 67 may be of limited value. Its use is complicated by bowel excretion of isotope and it is unlikely that this technique will reach the degree of refinement necessary for staging purposes (Nash et al. 1972) .
The poor-risk group in rectal cancer can be broadly defined as tumours located in the lower two-thirds of the rectum, of Dukes C stage and poor histological differentiation. Approximately 60% of rectal cancer occurs in the middle and lower thirds, about 35 % is poorly differentiated and about 50 % ofpatients coming to surgery have Dukes C tumours. Thus the potential role for radiotherapy in untreated, surgically operable, but poor-risk patients, patients with inoperable but apparently localized disease, and those with cancer recurring in the pelvis after surgery, is a very important one. Accurate staging procedures must be developed, and the possibility of a staging laparotomy considered. Lack of knowledge of extent of disease has led to a wide variety of treatment volumes; in some cases the pelvic field is extended to irradiate the lower lumbar region (inferior mesenteric artery), while in most centres irradiation is localized to the pelvis, or an even smaller volume concentrating on the rectal primary.
A second important obstacle to the effective use of radiotherapy, especially as primary management in inoperable disease, is the relative radioinsensitivity of adenocarcinoma of the rectum. Williams (1960) Figs 1 and 2 show, respectively, a prompt response in a lower para-aortic node, and regression of an anastomotic recurrence in colonic cancer, each receiving 4000 rad, given over four weeks with daily fractionation. The contrast between the ability of irradiation to produce enough tumour regression to secure the relief of symptoms, and the difficulty oferadicating local disease, stresses the importance of examining possible ways of enhancing the effectiveness of radiotherapy. There are various approaches to this problem, one of which is the association of radiotherapy and chemotherapy. At present the most striking results using a combined approach have been obtained in radiosensitive and chemosensitive tumours such as the lymphomas, acute leukwemia, Ewing's tumour and nephroblastoma, but the approach is worthy of serious consideration in the common solid tumours such as rectal cancer.
In conjunction with Dr Gordon Steel, we have been examining the effect of an injection of cyclophosphamide on the tumour response to a single fraction of radiation in an experimental mouse tumour. This tumour, the Lewis lung carcinoma, transplanted to the limb of the animal, is initially curable by amputation, but, if left, metastasizes to the lungs. Karrer et al. (1967) have previously used this system as a model for resected pulmonary carcinoma. In a preliminary study we have delivered a single fraction (2000, 4000, or 6000 rad) to different groups of mice at days 3, 7 or 12 after implantation and, in half the animals, followed this with an injection of cyclophosphamide at day 18. The results at day 7 show that, whereas 4000 rad does not achieve cure, the same dose combined with cyclophosphamide results in cure. The tumour control probability with and without cyclophosphamide is shown in Fig 3. It is important to note that the normal tissue reaction is not exaggerated by the combined approach. The timing of cyclophosphamide to the single fraction ofradiation is being examined in order to establish the optimal phasing of drug in relation to irradiation.
The most effective chemotherapeutic agent in colorectal cancer is 5-fluorouracil (5-FU), where responses can be obtained in 15-20% of patients (Krakoff 1972) . Such responses are usually incomplete and of short duration. In the early literature on this agent Heidelberger et al. (1958) reported that an experimental tumour unresponsive to either irradiation or 5-FU alone could be controlled by a combination of both. Since that time clinical studies in a wide variety of human tumours have been carried out, and some of these are summarized in Fig 4. (Vietti & Dale 1972) . In order to take advantage of short-term synergism between drug and radiation, modifications in radiation fractionation may be necessary, at least in part of the treatment, to allow the chemotherapeutic agent to be given with each fraction, while at the same time avoiding excessive damage to normal tissues (especially gut). The problem of adapting experimental observations to the clinical situation is difficult and probably best approached by examining the effects of single exposures of drug and radiation on lung or skin metastases where volume changes are quantifiable.
